CLAIMS

1. Use of an anti-FcRn antibody or an antigen-binding fragment thereof in the manufacture of a medicament for treating or preventing Graves' ophthalmopathy in a patient in need thereof, wherein the medicament is suitable for administration to the patient comprises (i) a therapeutically effective amount of the antibody or antigen-binding fragment; or (ii) a pharmaceutical composition comprising at least one pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody or antigen-binding fragment.

2. The use of claim 1, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence of SEQ ID No: 27 (HCDR1), an amino acid sequence of SEQ ID No: 28 (HCDR2), and an amino acid sequence of SEQ ID No: 29 (HCDR3); and a light chain variable region comprising an amino acid sequence of SEQ ID No: 30 (LCDR1), an amino acid sequence of SEQ ID No: 31 (LCDR2), and an amino acid sequence of SEQ ID No: 32 (LCDR3).

3. 3.The use of claim 1 or claim 2, wherein the antibody or antigen-binding fragment comprises (i) a heavy chain variable region comprising an amino acid sequence of SEQ ID No: 6; and a light chain variable region comprising an amino acid sequence of SEQ ID No: 16 or (ii) a heavy chain variable region comprising an amino acid sequence that is at least 90% identical to SEQ ID No: 6; and a light chain variable region comprising an amino acid sequence that is at least 90% identical to SEQ ID No: 16.

4. The use of any one of claims 1 to 3, wherein the antibody, antigen-binding fragment, or pharmaceutical composition is administered subcutaneously.

5. The use of any one of claims 1 to 4, wherein the antibody, antigen-binding fragment, or pharmaceutical composition is administered as a fixed dose.

6. The use of any one of claims 1 to 5, wherein the antibody, antigen-binding fragment, or pharmaceutical composition is suitable for administration once weekly or once every 2 weeks (bi-weekly).

7. The use of any one of claims 1 to 6, wherein the therapeutically effective amount of the antibody or antigen-binding fragment is:

    a. about 200 to 300 mg, 300 to 400 mg, about 400 to 500 mg, or about 500 to 600 mg administered once weekly;
    b. about 340 mg administered once weekly;
    c. about 550 to 650 mg, about 650 to 750 mg, or about 750 to 850 mg administered once weekly; and/or
    d. about 680 mg administered once weekly.

8. The use of any one of claims 1 to 7, wherein the therapeutically effective amount of the antibody or antigen-binding fragment is at least one dose of about 680 mg, followed by at least one dose of about 340 mg.

9. The use of claim 8, wherein the at least one dose of about 680 mg is to be administered subcutaneously or intravenously and/or wherein the at least one dose is about 340 mg is to be administered subcutaneously.

10. The use of claim 8, wherein the at least one dose of about 680 mg is about 3 doses and/or wherein the at least one dose of about 340 mg is about 3 doses.

11. The use of any one of claims 1 to 10, wherein the antibody, antigen-binding fragment, or pharmaceutical composition is to be administered alone or in combination with at least one additional therapeutic agent.

12. The use of any one of claims 1 to 11, wherein treatment reduces the level of at least one IgG in a sample from the patient.

13. The use of claim 12, wherein the at least one IgG comprises anti-TSHR IgG and/or anti-IGF-1R IgG.

14. The use of claim 13, wherein treatment reduces the level of anti-TSHR IgG and/or anti-IGF-1R IgG in a sample from the patient by at least about 30%, about 40%, about 50%, about 60%, about 70%, or about 80%.

15. The use of any one of claims 1 to 14, wherein treatment reduces the level of total serum IgG in a sample from the patient.

16. The use of claim 15, wherein treatment reduces the level of total serum IgG in a sample from the patient by at least about 40%, about 50%, about 60%, about 70%, or about 80%.

17. A kit comprising an anti-FcRn antibody or an antigen-binding fragment thereof and

instructions for use of the antibody or antigen-binding fragment for use in treating or preventing Graves' ophthalmopathy in a patient in need thereof.

18. The kit of claim 17, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence of SEQ ID No: 27 (HCDR1), an amino acid sequence of SEQ ID No: 28 (HCDR2), and an amino acid sequence of SEQ ID No: 29 (HCDR3); and a light chain variable region comprising an amino acid sequence of SEQ ID No: 30 (LCDR1), an amino acid sequence of SEQ ID No: 31 (LCDR2), and an amino acid sequence of SEQ ID No: 32 (LCDR3).

19. The kit of claim 17 or claim 18, wherein the antibody or antigen-binding fragment comprises (i) a heavy chain variable region comprising an amino acid sequence of SEQ ID No: 6; and a light chain variable region comprising an amino acid sequence of SEQ ID No: 16 or (ii) a heavy chain variable region comprising an amino acid sequence that is at least 90% identical to SEQ ID No: 6; and a light chain variable region comprising an amino acid sequence that is at least 90% identical to SEQ ID No: 16.

20. The kit of any one of claims 17 to 19, wherein the kit further comprises at least one additional therapeutic agent.